Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2021.239 | Retrospective cohort study for early detection of new-onset chronic diseases in recovered COVID-19 patients using population-based datasets | Prof. WONG Grace Lai Hung |
| 2022.656 | A Phase 2a, Randomized, Blinded, Multicenter Study Investigating a Combination of AB-729 and VTP-300 in Virologically-Suppressed Chronic Hepatitis B Participants | Prof. WONG Grace Lai Hung |
| 2013.550 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B | Prof. WONG Grace Lai Hung |
| 2012.357 | An open-label trial of 48-week peginterferon alfa-2a (PEGASYS) to assess the sustained response of chronic hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy | Prof. WONG Grace Lai Hung |
| 2013.316 | A randomized controlled trial of a new screening strategy for varices based on liver and spleen stiffness measurement (LSSM) in cirrhotic patients | Dr. WONG Grace Lai Hung |
| 2009.381 | Prevention of recurrent idiopathic gastroduoden ulcer bleeding: a double-blind randomized trial | Dr. WONG Grace Lai Hung |
| 2013.551 | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B | Prof. WONG Grace Lai Hung |
| 2013.105 | A randomized controlled trial on the efficacy of tenofovir disoproxil fumarate (TDF)-switch therapy in chronic hepatitis B patients with incomplete response to entecavir | Dr. WONG Grace Lai Hung |
| 2022.676 | A Phase 2 Study Evaluating the Efficacy and Safety of VIR-3434 and/or VIR-2218 Containing Regimens in HBeAg-negative Participants with Low Viral Burden of Chronic Hepatitis B Infection (THRIVE) | Prof. WONG Grace Lai Hung |
| 2021.091 | Comparative Risk of HCC in CHB Patients Receiving ETV or TDF-based Treatment: IPD Meta-Analysis Protocol |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2022.480 | A PHASE II, RANDOMISED, ADAPTIVE, OPEN-LABEL PLATFORM TRIAL TO EVALUATE EFFICACY AND SAFETY OF MULTIPLE COMBINATION THERAPIES IN PARTICIPANTS WITH CHRONIC HEPATITIS B |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2023.273 | A PHASE I STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7565020 IN HEALTHY PARTICIPANTS AND IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION |
Prof. WONG Grace Lai Hung 35053759 |
| 2021.427 | A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2023.151 | A phase 2b, open-label study to evaluate the efficacy, safety, tolerability, immunogenicity and treatment regimens of VTP-300 combined with low-dose nivolumab in Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung Grace LH Wong |
| 2021.112 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2023.268 | A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection | Prof. WONG Grace Lai Hung |
| 2021.106 | Prospective evaluation of a fast-track treatment pathway for patients with chronic hepatitis B under primary care |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2020.544 | Deep learning of combined clinical data and CT images in patients with chronic viral hepatitis – risk prediction and complication reduction to facilitate eliminating viral hepatitis by year 2030 |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2021.223 | Drug-Drug Interactions in Patients Treated with DAAs in Hong Kong | Prof. WONG Grace Lai Hung |
| 2020.310 | A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled Study Evaluating Treatment Intensification with ABI-H0731 in Subjects with Chronic Hepatitis B Infection on Nucleos(t)ide Reverse Transcriptase Inhibitors | Prof. WONG Grace Lai Hung |
| 2022.509 | Sodium-glucose co-transporter-2 inhibitor (SGLT2i) to prevent of liver complications in patients with chronic hepatitis B and diabetes mellitus: a double-blind, randomised, placebo-controlled trial |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2022.678 | A Phase 2 Study Evaluating the Efficacy and Safety of VIR-3434 and/or VIR-2218 Containing Regimens in Participants with Chronic Hepatitis B Infection (STRIVE) | Prof. WONG Grace Lai Hung |
| 2020.459 | Elimination of chronic hepatitis B in Hong Kong – to meet the WHO goals |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2020.615 | Evaluation of AFP, AFP-L3, PIVKA-II and GALAD Score (Gender, Age, AFP-L3, AFP, DCP/PIVKA-II) for risk assessment of Hepatocellular Carcinoma (HCC) | Prof. WONG Grace Lai Hung |
| 2022.653 | A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection | Prof. WONG Grace Lai Hung |
| 2023.039 | A Phase 1b Multi-Center, Open-Label, Dose-Escalation, Prime and Boost Vaccination Evaluation of Two Chimpanzee Adenoviral Vectors in Adult Participants With Chronic HBV Infection Who Are Currently Receiving HBV Nucleos(t)ide Reverse Transcriptase Inhibitors | Prof. WONG Grace Lai Hung |
| 2022.552 | Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1) |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2023.200 | A Phase 1, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Orally Administered ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single-Ascending Doses (Part 1) and Multiple-Ascending Doses in Healthy Volunteers (Part 2), and Multiple Doses in Subjects with Chronic Hepatitis B (Part 3) |
Prof. WONG Grace Lai Hung Grace LH Wong |
| 2021.297 | A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNa in Subjects with Chronic Hepatitis B Virus Infection |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2022.601 | Real-World Data to Assess HCV Patients Treated with SOF/VEL without RBV |
Prof Wong Grace Lai Hung 黃麗虹教授 |
| 2020.509 | A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection |
Prof Wong Grace Lai Hung 黃麗虹 |
| 2021.517 | A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects with Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2023.265 | A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB) |
Prof. WONG Grace Lai Hung Lai Hung Wong |
| 2022.324 | Chronic kidney disease progression in chronic hepatitis B patients on tenofovir alafenamide (TAF) versus entecavir |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2024.115 | Behavior, Aspirations and Treatment needs of people living with hepatitis B | Prof. WONG Grace Lai Hung |
| 2025.372 | A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects with Chronic Hepatitis B Virus Infection (B-SUPREME) | Prof. WONG Grace Lai Hung |
| 2024.313 | A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod Alone and in Combinations in Subjects with Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung Wai Sun Vincent Wong |
| 2024.361 | Overcoming Inequalities in Health to Eliminate Hepatitis – Real-World Evidence from a Territory-Wide Cohort |
Prof. WONG Grace Lai Hung Lai Hung Grace Wong |
| 2024.002 | A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2024.633 | Universal screening for hepatitis delta virus (HDV) in individuals living with HIV/HBV coinfection and HBV-related HCC | Prof. WONG Grace Lai Hung |
| 2024.057 | A Long-Term Follow-up Study for Subjects with Chronic Hepatitis B Previously Treated with Imdusiran (AB-729) | Prof. WONG Grace Lai Hung |
| 2024.058 | A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2023.344 | A Phase 1/2 Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BW-20507 in Healthy Subjects, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Subjects with Chronic HBV Infection and a Long-term Study to Evaluate the Safety, Tolerability, and Efficacy of BW-20507 in Subjects with Chronic HBV Infection | Prof. WONG Grace Lai Hung |
| 2025.296 | A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNα-2a in Subjects with Chronic Hepatitis B |
Prof. WONG Grace Lai Hung Grace Wong |
| 2023.684 | A phase II clinical study to evaluate the safety, efficacy, and pharmacokinetics of RBD1016 injection in participants with chronic hepatitis B | Prof. WONG Grace Lai Hung |
| 2018.297 | A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects |
Prof. WONG Grace Lai Hung 陳力元教授 |
| 2018.177 | Secular trend of hepatic events in patients with diabetes mellitus - a retrospective observational cohort study |
Dr. WONG Grace Lai Hung 黃麗虹 |
| 2019.690 | Response after End of Treatment with Antivirals in Chronic Hepatitis B | Prof. WONG Grace Lai Hung |
| 2018.647 | Gastrointestinal and hepatic adverse events of immune checkpoint inhibitors (ICI) - a territory-wide observational cohort study | Dr. WONG Grace Lai Hung |
| 2018.646 | Disease burden of chronic viral hepatitis in Hong Kong – towards eliminating viral hepatitis by year 2030 according to World Health Organization (WHO) targets | Dr. WONG Grace Lai Hung |
Page 36 of 268.